Urogen Pharma (NASDAQ:URGN) Price Target Cut to $40.00 by Analysts at HC Wainwright

Key Points

• HC Wainwright reduced Urogen Pharma's price target from $50.00 to $40.00, reflecting a 125.35% potential upside from the current stock price while maintaining a "buy" rating.
• Urogen Pharma reported a quarterly EPS of ($1.05), missing estimates by ($0.23), and had a negative net margin of 164.44%.
• Insiders have sold a total of 17,833 shares worth approximately $280,567 in the last three months, indicating potential concerns regarding the company's stock performance.

Urogen Pharma (NASDAQ:URGN - Get Free Report) had its price target dropped by research analysts at HC Wainwright from $50.00 to $40.00 in a report released on Monday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price target would suggest a potential upside of 101.09% from the company's current price. HC Wainwright also issued estimates for Urogen Pharma's Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($3.37) EPS, Q1 2026 earnings at ($0.60) EPS, Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at $0.01 EPS and FY2026 earnings at ($1.18) EPS.

Several other equities research analysts have also commented on the stock. The Goldman Sachs Group set a $16.00 price target on shares of Urogen Pharma and gave the company a "neutral" rating in a research note on Friday, June 13th. D. Boral Capital restated a "buy" rating and set a $25.00 target price on shares of Urogen Pharma in a report on Tuesday, August 5th. Guggenheim restated a "buy" rating and set a $30.00 target price (up from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. Oppenheimer set a $31.00 target price on shares of Urogen Pharma and gave the stock a "buy" rating in a report on Friday, June 13th. Finally, Scotiabank restated an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $31.43.

Urogen Pharma Stock Performance

Urogen Pharma stock traded down $0.19 during trading on Monday, reaching $19.89. 347,363 shares of the company's stock were exchanged, compared to its average volume of 1,569,364. The company's 50-day moving average is $15.21 and its two-hundred day moving average is $11.59. The firm has a market cap of $920.20 million, a price-to-earnings ratio of -5.98 and a beta of 1.12. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $21.01.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). The company had revenue of $24.22 million during the quarter, compared to analyst estimates of $23.06 million. Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. Analysts anticipate that Urogen Pharma will post -3.12 EPS for the current year.

Insider Activity at Urogen Pharma

In related news, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $17.69, for a total transaction of $176,900.00. Following the sale, the insider directly owned 148,229 shares in the company, valued at $2,622,171.01. This trade represents a 6.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Jason Drew Smith sold 7,522 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $19.14, for a total transaction of $143,971.08. Following the completion of the transaction, the general counsel owned 41,492 shares in the company, valued at $794,156.88. This trade represents a 15.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,833 shares of company stock worth $457,467 over the last ninety days. 4.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. CWM LLC lifted its position in shares of Urogen Pharma by 6,047.1% during the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after acquiring an additional 5,140 shares during the period. Lazard Asset Management LLC purchased a new stake in shares of Urogen Pharma in the fourth quarter worth about $67,000. GAMMA Investing LLC lifted its holdings in shares of Urogen Pharma by 6,908.4% in the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock worth $83,000 after buying an additional 7,392 shares in the last quarter. Aquatic Capital Management LLC purchased a new stake in shares of Urogen Pharma in the fourth quarter worth about $101,000. Finally, ProShare Advisors LLC purchased a new stake in Urogen Pharma in the fourth quarter valued at approximately $137,000. Institutional investors and hedge funds own 91.29% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.